|
|||||
|
|
Phase II study with methyl-6[[[2-chloroethyl) nitrosoamino] carbonyl] amino]-6-deoxy-alpha-D-glucopyranoside (MCNU) in hematological malignancies |
|
| Authors: | T Masaoka K Kimura T Miyazaki K Sakurada H Saitoh M Morioka N Fujimoto M Musashi A Wakui M Yokoyama R Kanamaru M Oguro T Takagi C Konda T Saitoh I Nakao S Harashima Y Ohhashi Y Sakai T Sasaki R Ohno Y Katoh K Yamada Y Hirota T Takada A Hoshino K Ohara O Kamiya T Kojima K Nagata T Nakamura M Sasada T Yonezawa T Tsubakio Y Kanayama T Kitani N Taniguchi K Yasunaga Y Okamoto H Fujitake A Ohkubo A Horiuchi K Tsubaki T Takubo H Shibata H Kawagoe M Hirata T Matsubuchi K Nagai S Fujita |
| Abstract: | A total of 117 cases with hematological malignancies were treated with MCNU at doses of 70-100 mg/m2. Following are the results obtained. 1. MCNU showed a marked depression of cells in the cases with CML, polycythemia vera and thrombocythemia. The low level of cells was maintained for 2 to 7 months. 2. A good response was observed in several cases with blastic crises of CML. 3. No response was observed in two cases with acute leukemia. 4. Although a fair response was observed in several cases with malignant lymphoma or multiple myeloma, moderate bone marrow suppression was observed in a majority of the cases. |
| Keywords: | |